Phaim Phaim

Pipeline &



Antigen-based novel approach designed to restore healthy immune tolerance in T1DM patients. With its uniquely T1DM-specific immune modulator approach, our AIM therapy is designed to change the immune process specific to T1DM autoimmunity beneficially. It is perfectly suited to arrest T1DM autoimmunity, not only in patients with the full blown disease, but in those who have disease that is not yet clinically manifest (pre-Type 1 diabetes). It is non-immune suppressive, thus particularly advantageous for children who are the fastest growing population developing the disease.

This compound is now entering its Phase I/II development after successful pre-clinical data.

CTLA4-Ig (abatacept):

This is marketed as Orencia by Bristol-Myer Squibb for rheumatoid arthritis. A recent Phase 2 clinical trial, initiated and chaired by Tihamer Orban MD, successfully used the drug with a novel application for T1DM. In the trial abatacept significantly slowed down the autoimmunity, preserved self-insulin production and significantly improved blood sugar control. Abatacept beneficially altered the immune cells of T1DM patients and showed no appreciable side-effect even in young children. The drug is now in a clinical trial initiated by Tihamer Orban MD to prevent the development of T1DM. The Company intends to develop the drug for T1DM autoimmunity, for both T1DM patients and pre-diabetics.

This drug is ready for a Phase 3 trial in this new indication.

CTLA4-Ig (abatacept)
in combination with an antigen based AIM therapy:

This is marketed as Orencia by Bristol-Myer Squibb for rheumatoid arthritis. This is a combination approach utilising the complementary mode of action of abatacept and a T1DM-specific antigen AIM therapy to achieve a synergistic effect. The combination is specific for T1DM autoimmunity and designed to be applied as therapy as well as prevention.

This combination product is in preclinical development.


Patent to secure antigenic identification for psoriatic skin conditions is currently undergoing development. We will be taking our AIM therapy into this auto-immune skin disease shortly.